AS­CO loom­ing, Loxo, Bay­er line up a quick shot at FDA OK for their ground­break­ing ap­proach to can­cer ther­a­py

Just days away from learn­ing more about Loxo On­col­o­gy’s $LOXO close­ly-watched can­cer drug larotrec­tinib at AS­CO, the com­pa­ny is set­ting the stage with the news that the FDA has come through with a fast-paced pri­or­i­ty re­view plan to whisk the drug through an agency in­spec­tion process.

The short­ened pri­or­i­ty game plan gives Loxo and its part­ners at Bay­er a mar­ket­ing de­ci­sion date of No­vem­ber 26 with an­a­lysts giv­ing this one good odds of suc­cess based on the da­ta we’ve seen.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER